AstraZeneca’s Oncology Growth Is Outrunning The Farxiga Decline (NYSE:AZN)
· seekingalpha.com
AstraZeneca is a Buy at 18.46x forward earnings; as specialty medicines drive double-digit growth and Q3 revenue rose 7%. Read more on AZN stock here.
My research is based on key market themes and works to identify setups that provide asymmetrical risk/reward profiles within these niches. My portfolio is curre...